Next Article in Journal
Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice
Next Article in Special Issue
Tissue-Resident T Cells in Chronic Relapsing–Remitting Intestinal Disorders
Previous Article in Journal
Rho-Proteins and Downstream Pathways as Potential Targets in Sepsis and Septic Shock: What Have We Learned from Basic Research
Previous Article in Special Issue
Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease
Review

Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury

by 1,2 and 1,2,3,*
1
Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
2
Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA
3
Central Texas Veterans Health Care System, Temple, TX 78712, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Marc Basson
Cells 2021, 10(8), 1846; https://doi.org/10.3390/cells10081846
Received: 30 June 2021 / Revised: 16 July 2021 / Accepted: 17 July 2021 / Published: 21 July 2021
Recent studies on liver disease burden worldwide estimated that cirrhosis is the 11th most common cause of death globally, and there is a great need for new therapies to limit the progression of liver injuries in the early stages. Cholestasis is caused by accumulation of hydrophobic bile acids (BA) in the liver due to dysfunctional BA efflux or bile flow into the gall bladder. Therefore, strategies to increase detoxification of hydrophobic BA and downregulate genes involved in BA production are largely investigated. Farnesoid X receptor (FXR) has a central role in BA homeostasis and recent publications revealed that changes in autophagy due to BA-induced reactive oxygen species and increased anti-oxidant response via nuclear factor E2-related factor 2 (NRF2), result in dysregulation of FXR signaling. Several mechanistic studies have identified new dysfunctions of the cholestatic liver at cellular and molecular level, opening new venues for developing more performant therapies. View Full-Text
Keywords: FXR; liver; cholestasis; obeticholic acid; rifampicin; autophagy FXR; liver; cholestasis; obeticholic acid; rifampicin; autophagy
Show Figures

Figure 1

MDPI and ACS Style

Petrescu, A.D.; DeMorrow, S. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. Cells 2021, 10, 1846. https://doi.org/10.3390/cells10081846

AMA Style

Petrescu AD, DeMorrow S. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. Cells. 2021; 10(8):1846. https://doi.org/10.3390/cells10081846

Chicago/Turabian Style

Petrescu, Anca D., and Sharon DeMorrow. 2021. "Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury" Cells 10, no. 8: 1846. https://doi.org/10.3390/cells10081846

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop